SCHEMBL20147585

SCHEMBL20147585

CC(C)N1CCC(NC(=O)c2cccc(F)c2)CC1

nearest known ligand 0.63

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.61
MEN1 O00255 4/20 0.61
GRM5 P41594 4/20 0.60
CCR3 P51677 1/20 0.57
HRH3 Q9Y5N1 2/20 0.56
ALDH1A1 P00352 2/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
KDM5A P29375 1/20 0.55
TSHR P16473 1/20 0.53
ACKR3 P25106 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21779877 0.87 GRM5 (0.59) KMT2AMEN1GRM5CCR3L3MBTL1
SCHEMBL10212614 0.85 GRM5 (0.62) KMT2AMEN1GRM5CCR3HRH3
SCHEMBL13847098 0.85 KMT2A (0.65) KMT2AMEN1GRM5CCR3ALDH1A1
SCHEMBL29973192 0.85 KMT2A (0.65) KMT2AMEN1GRM5CCR3ALDH1A1
SCHEMBL2559523 0.85 HRH3 (0.54) KMT2AMEN1HRH3ALDH1A1
SCHEMBL20147581 0.84 HRH3 (0.68) KMT2AMEN1CCR3HRH3TSHR
SCHEMBL18389994 0.84 HRH3 (0.67) KMT2AMEN1HRH3ALDH1A1
SCHEMBL19464802 0.84 DRD4 (0.60) KMT2AMEN1HRH3ALDH1A1
SCHEMBL1116603 0.83 GRM5 (0.77) KMT2AMEN1GRM5CCR3L3MBTL1
SCHEMBL21651961 0.82 CCR3 (0.67) KMT2AMEN1GRM5CCR3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-01-05 US disclosed
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 KMT2A 1112/4885MEN1 653/4885GRM5 1363/4885
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 KMT2A 1112/4885MEN1 653/4885GRM5 1363/4885
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 KMT2A 1112/4885MEN1 653/4885GRM5 1363/4885
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 KMT2A 1112/4885MEN1 653/4885GRM5 1363/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 KMT2A 1112/4885MEN1 653/4885GRM5 1363/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 KMT2A 1112/4885MEN1 653/4885GRM5 1363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.